Negative regulatory approaches to the attenuation of Toll-like receptor signaling

Experimental and Molecular Medicine

Volumn 45, Issue 2, 2013, Pages

  Anwar, Muhammad Ayaz ^a   Basith, Shaherin ^a   Choi, Sangdun ^a  

^a Ajou University   (South Korea)

Author keywords

Inflammatory diseases; Inhibitors; Innate immune system; MiRNA; Toll like receptors

Indexed keywords

2 ARACHIDONOYLGLYCEROPHOSPHORYLCHOLINE; ADAPTOR PROTEIN; CHLOROQUINE; DOCKING PROTEIN; DV 1179; E 567; E 6446; EM 77; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ERITORAN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYCHLOROQUINE; IMIDAZOQUINOLINE DERIVATIVE; IMO 3100; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; IPH 32XX; IRS 954; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MYELOID DIFFERENTIATION FACTOR 88; PROPIDIUM IODIDE; RECEPTOR BLOCKING AGENT; ST 2825; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYTOKINE; LIGAND;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; AUTOPHAGY; CHRONIC INFLAMMATION; CYTOKINE RELEASE; HUMAN; IMMUNOREGULATION; INFLAMMATION; INFLAMMATORY DISEASE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; NEGATIVE FEEDBACK; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION; UBIQUITINATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DRUG ANTAGONISM; IMMUNOLOGY; METABOLISM;

ANIMALS; CYTOKINES; HUMANS; LIGANDS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84875932685     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.28     Document Type: Review

References (122)

1. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996; 86: 973-983.
2. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397.
3. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-2088.
4. Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999; 189: 615-625.
5. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y et al. Cutting Edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-3752.
6. Oldenburg M, Kruger A, Ferstl R, Kaufmann A, Nees G, Sigmund A et al. TLR13 recognizes bacterial 23 S rRNA devoid of erythromycin resistanceforming modification. Science 2012; 337: 1111-1115.
7. Kawai T, Akira S. TLR signaling. Semin Immunol 2007; 19: 24-32.
8. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 2004; 5: 190-198.
9. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 1999; 401: 811-815.
10. Wang Y, Chen T, Han C, He D, Liu H, An H et al. Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood 2007; 110: 962-971.
11. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1: 135-145.
12. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature 2005; 438: 364-368.
13. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
14. Doyle SE, O'Connell RM, Miranda GA, Vaidya SA, Chow EK, Liu PT et al. Toll-like receptors induce a phagocytic gene program through p38. J Exp Med 2004; 199: 81-90.
15. Werling D, Hope JC, Howard CJ, Jungi TW. Differential production of cytokines, reactive oxygen and nitrogen by bovine macrophages and dendritic cells stimulated with Toll-like receptor agonists. Immunology 2004; 111: 41-52.
16. Nijhuis MM, Pasterkamp G, Sluis NI, de Kleijn DP, Laman JD, Ulfman LH. Peptidoglycan increases firm adhesion of monocytes under flow conditions and primes monocyte chemotaxis. J Vasc Res 2007; 44: 214-222.
17. Kaisho T, Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006; 117: 979-987; quiz 988.
18. Salaun B, Romero P, Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 2007; 37: 3311-3318.
19. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987-995.
20. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005; 560: 11-18.
21. Palm NW, Medzhitov R. Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009; 227: 221-233.
22. Li M, Zhou Y, Feng G, Su SB. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr Mol Med 2009; 9: 365-374.
23. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 2012; 35: 1297-1316.
24. Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity 2003; 19: 837-847.
25. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via toll-like receptor 3. Arthritis Rheumat 2005; 52: 2656-2665.
26. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating tlr2 signaling are present in human plasma and breast milk. J Immunol 2003; 171: 6680-6689.
27. LeBouder E, Rey-Nores JE, Rushmere NK, Grigorov M, Lawn SD, Affolter M et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003; 171: 6680-6689.
28. Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000; 165: 6682-6686.
29. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cellbound LPS to plasma lipoproteins. J Clin Invest 2001; 108: 485-493.
30. Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic V et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001; 166: 6633-6639.
31. Wald D, Qin J, Zhao Z, Qian Y, Naramura M, Tian L et al. SIGIRR, a negative regulator of Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2003; 4: 920-927.
32. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004; 5: 373-379.
33. Basith S, Manavalan B, Govindaraj RG, Choi S. In silico approach to inhibition of signaling pathways of Toll-like receptors 2 and 4 by ST2L. PLoS One 2011; 6: e23989.
34. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A et al. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol 2005; 6: 571-578.
35. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-364.
36. Palsson-McDermott EM, Doyle SL, McGettrick AF, Hardy M, Husebye H, Banahan K et al. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat Immunol 2009; 10: 579-586.
37. Doyle SL, Husebye H, Connolly DJ, Espevik T, O'Neill LA, McGettrick AF. The GOLD domain-containing protein TMED7 inhibits TLR4 signalling from the endosome upon LPS stimulation. Nat Commun 2012; 3: 707.
38. Wang T, Chuang TH, Ronni T, Gu S, Du YC, Cai H et al. Flightless I homolog negatively modulates the TLR pathway. J Immunol 2006; 176: 1355-1362.
39. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie AG. The human adaptor SARM negatively regulates adaptor protein TRIFdependent Toll-like receptor signaling. Nat Immunol 2006; 7: 1074-1081.
40. Siednienko J, Halle A, Nagpal K, Golenbock DT, Miggin SM. TLR3-mediated IFN-beta gene induction is negatively regulated by the TLR adaptor MyD88 adaptor-like. Eur J Immunol 2010; 40: 3150-3160.
41. Seregin SS, Aldhamen YA, Appledorn DM, Aylsworth CF, Godbehere S, Liu CJ et al. TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo. PLoS One 2011; 6: e22064.
42. Peng Q, O'Loughlin JL, Humphrey MB. DOK3 negatively regulates LPS responses and endotoxin tolerance. PLoS One 2012; 7: e39967.
43. Han C, Jin J, Xu S, Liu H, Li N, Cao X. Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b. Nat Immunol 2010; 11: 734-742.
44. Shimauchi H, Ogawa T, Okuda K, Kusumoto Y, Okada H. Autoregulatory effect of interleukin-10 on proinflammatory cytokine production by Porphyromonas gingivalis lipopolysaccharide-tolerant human monocytes. Infect Immun 1999; 67: 2153-2159.
45. Troutman TD, Hu W, Fulenchek S, Yamazaki T, Kurosaki T, Bazan JF et al. Role for B-cell adapter for PI3K (BCAP) as a signaling adapter linking Toll-like receptors (TLRs) to serine/threonine kinases PI3K/Akt. Proc Natl Acad Sci 2012; 109: 273-278.
46. Kawagoe T, Takeuchi O, Takabatake Y, Kato H, Isaka Y, Tsujimura T et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol 2009; 10: 965-972.
47. Yuk JM, Shin DM, Lee HM, Kim JJ, Kim SW, Jin HS et al. The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat Immunol 2011; 12: 742-751.
48. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol 2007; 7: 454-465.
49. Kayagaki N, Phung Q, Chan S, Chaudhari R, Quan C, O'Rourke KM et al. A deubiquitinase that regulates type I interferon production. Science 2007; 318: 1628-1632.
50. Tanaka T, Grusby MJ, Kaisho T. PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit. Nat Immunol 2007; 8: 584-591.
51. Saitoh T, Tun-Kyi A, Ryo A, Yamamoto M, Finn G, Fujita T et al. Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 2006; 7: 598-605.
52. Tun-Kyi A, Finn G, Greenwood A, Nowak M, Lee TH, Asara JM et al. Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. Nat Immunol 2011; 12: 733-741.
53. Yu Y, Hayward GS. The ubiquitin E3 ligase RAUL negatively regulates type I interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity 2010; 33: 863-877.
54. Turer EE, Tavares RM, Mortier E, Hitotsumatsu O, Advincula R, Lee B et al. Homeostatic MyD88-dependent signals cause lethal inflammation in the absence of A20. J Exp Med 2008; 205: 451-464.
55. Skaug B, Chen J, Du F, He J, Ma A, Chen ZJ. Direct, noncatalytic mechanism of IKK inhibition by A20. Mol Cell 2011; 44: 559-571.
56. Zhou F, Zhang X, van Dam H, Ten Dijke P, Huang H, Zhang L. Ubiquitinspecific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. J Biol Chem 2012; 287: 11002-11010.
57. He X, Li Y, Li C, Liu LJ, Zhang XD, Liu Y et al. USP2a negatively regulates IL-1beta- and virus-induced NF-kappaB activation by deubiquitinating TRAF6. J Mol Cell Biol 2012; e-pub ahead of print 19 May 2012; doi:10.1093/jmcb/mjs024.
58. Zhong B, Liu X, Wang X, Liu X, Chang SH, Li H et al. Regulation of TLRtriggered innate immune response by ubiquitin-specific protease 25. J Immunol 2012; 188: (Meeting Abstract Supplement) 180.8.
59. Ananieva O, Darragh J, Johansen C, Carr JM, McIlrath J, Park JM et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 2008; 9: 1028-1036.
60. Risco A, del Fresno C, Mambol A, Alsina-Beauchamp D, MacKenzie KF, Yang HT et al. P38g and p38d kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc Natl Acad Sci 2012; 109: 11200-11205.
61. Yang HT, Wang Y, Zhao X, Demissie E, Papoutsopoulou S, Mambole A et al. NF-kappaB1 inhibits TLR-induced IFN-beta production in macrophages through TPL-2-dependent ERK activation. J Immunol 2011; 186: 1989-1996.
62. Ajibade AA, Wang Q, Cui J, Zou J, Xia X, Wang M et al. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 2012; 36: 43-54.
63. An H, Hou J, Zhou J, Zhao W, Xu H, Zheng Y et al. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 2008; 9: 542-550.
64. An H, Zhao W, Hou J, Zhang Y, Xie Y, Zheng Y et al. SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production. Immunity 2006; 25: 919-928.
65. Xu S, Liu X, Bao Y, Zhu X, Han C, Zhang P et al. Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps-SHP-2 pathway. Nat Immunol 2012; 13: 551-559.
66. Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood 2007; 109: 4313-4319.
67. Zhao W, Wang L, Zhang M, Wang P, Zhang L, Yuan C et al. Peroxisome proliferator-activated receptor gamma negatively regulates IFN-beta production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-beta promoter. J Biol Chem 2011; 286: 5519-5528.
68. Kawana H, Karaki H, Higashi M, Miyazaki M, Hilberg F, Kitagawa M et al. CD44 suppresses TLR-mediated inflammation. J Immunol 2008; 180: 4235-4245.
69. Lee SM, Kim EJ, Suk K, Lee WH. CD300F blocks both MyD88 and TRIFmediated TLR signaling through activation of Src homology region 2 domain-containing phosphatase 1. J Immunol 2011; 186: 6296-6303.
70. Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 2009; 10: 340-347.
71. Wang L, Gordon RA, Huynh L, Su X, Park Min KH, Han J et al. Indirect inhibition of Toll-like receptor and type I interferon responses by ITAM-coupled receptors and integrins. Immunity 2010; 32: 518-530.
72. Kagan JC, Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006; 125: 943-955.
73. Campo GM, Avenoso A, D'Ascola A, Scuruchi M, Prestipino V, Nastasi G et al. Adenosine A2A receptor activation and hyaluronan fragment inhibition reduce inflammation in mouse articular chondrocytes stimulated with interleukin-1beta. FEBS J 2012; 279: 2120-2133.
74. Okazaki N, Hazeki K, Izumi T, Nigorikawa K, Hazeki O. C5a controls TLRinduced IL-10 and IL-12 production independent of phosphoinositide 3-kinase. J Biochem 2011; 149: 265-274.
75. Shi M, Deng W, Bi E, Mao K, Ji Y, Lin G et al. TRIM30 alpha negatively regulates TLR-mediated NF-kappa B activation by targeting TAB2 and TAB3 for degradation. Nat Immunol 2008; 9: 369-377.
76. Zhao W, Wang L, Zhang M, Yuan C, Gao C. E3 ubiquitin ligase tripartite motif 38 negatively regulates TLR-mediated immune responses by proteasomal degradation of TNF receptor-associated factor 6 in macrophages. J Immunol 2012; 188: 2567-2574.
77. Xue Q, Zhou Z, Lei X, Liu X, He B, Wang J et al. TRIM38 negatively regulates TLR3-mediated IFN-b signaling by targeting TRIF for degradation. PLoS One 2012; 7: e46825.
78. Yoshida H, Jono H, Kai H, Li JD. The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 2005; 280: 41111-41121.
79. Kuwata H, Matsumoto M, Atarashi K, Morishita H, Hirotani T, Koga R et al. IkappaBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. Immunity 2006; 24: 41-51.
80. Manavalan B, Basith S, Choi YM, Lee G, Choi S. Structure-function relationship of cytoplasmic and nuclear IkappaB proteins: an in silico analysis. PLoS One 2010; 5: e15782.
81. Carmody RJ, Ruan Q, Palmer S, Hilliard B, Chen YH. Negative regulation of toll-like receptor signaling by NF-kappaB p50 ubiquitination blockade. Science 2007; 317: 675-678.
82. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469: 323-335.
83. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 2008; 456: 264-268.
84. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 2008; 456: 259-263.
85. Inomata M, Niida S, Shibata K-i, Into T. Regulation of Toll-like receptor signaling by NDP52-mediated selective autophagy is normally inactivated by A20. Cell Mol Life Sci 2012; 69: 963-979.
86. Ramirez-Carrozzi VR, Nazarian AA, Li CC, Gore SL, Sridharan R, Imbalzano AN et al. Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev 2006; 20: 282-296.
87. Yan Q, Carmody RJ, Qu Z, Ruan Q, Jager J, Mullican SE et al. Nuclear factor-kappaB binding motifs specify Toll-like receptor-induced gene repression through an inducible repressosome. Proc Natl Acad Sci USA 2012; 109: 14140-14145.
88. Whitmore MM, Iparraguirre A, Kubelka L, Weninger W, Hai T, Williams BR. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol 2007; 179: 3622-3630.
89. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009; 137: 47-59.
90. Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol 2009; 30: 447-454.
91. Kimura A, Naka T, Nakahama T, Chinen I, Masuda K, Nohara K et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J Exp Med 2009; 206: 2027-2035.
92. Carrick DM, Lai WS, Blackshear PJ. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther 2004; 6: 248-264.
93. Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 2009; 458: 1185-1190.
94. Iwasaki H, Takeuchi O, Teraguchi S, Matsushita K, Uehata T, Kuniyoshi K et al. The IkappaB kinase complex regulates the stability of cytokineencoding mRNA induced by TLR-IL-1 R by controlling degradation of regnase-1. Nat Immunol 2011; 12: 1167-1175.
95. Li M, Cao W, Liu H, Zhang W, Liu X, Cai Z et al. MCPIP1 down-regulates IL-2 expression through an ARE-independent pathway. PLoS One 2012; 7: e49841.
96. O'Neill LA, Sheedy FJ, McCoy CE. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 2011; 11: 163-175.
97. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. Micro-RNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci 2007; 104: 1604-1609.
98. Huang RS, Hu GQ, Lin B, Lin ZY, Sun CC. MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages. J Investig Med 2010; 58: 961-967.
99. Tang B, Xiao B, Liu Z, Li N, Zhu ED, Li BS et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett 2010; 584: 1481-1486.
100. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci USA 2009; 106: 2735-2740.
101. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082-5089.
102. Gottwein E, Mukherjee N, Sachse C, Frenzel C, Majoros WH, Chi JT et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007; 450: 1096-1099.
103. Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y et al. Regulation of the germinal center response by microRNA-155. Science 2007; 316: 604-608.
104. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007; 316: 608-611.
105. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci 2009; 106: 7113-7118.
106. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486.
107. Zhao JL, Rao DS, Boldin MP, Taganov KD, O'Connell RM, Baltimore D. NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 2011; 108: 9184-9189.
108. Chassin C, Kocur M, Pott J, Duerr CU, Gutle D, Lotz M et al. miR-146a mediates protective innate immune tolerance in the neonate intestine. Cell Host Microbe 2010; 8: 358-368.
109. 109Liu X, Zhan Z, Xu L, Ma F, Li D, Guo Z et al. MicroRNA-148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIalpha. J Immunol 2010; 185: 7244-7251.
110. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11: 141-147.
111. Kužnik A, Benčina M, Švajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011; 186: 4794-4804.
112. Duramad O, Fearon KL, Chang B, Chan JH, Gregorio J, Coffman RL et al. Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol 2005; 174: 5193-5200.
113. Erridge C, Kennedy S, Spickett CM, Webb DJ. Oxidized phospholipid inhibition of toll-like receptor (TLR) signaling is restricted to TLR2 and TLR4: roles for CD14, LPS-binding protein, and MD2 as targets for specificity of inhibition. J Biol Chem 2008; 283: 24748-24759.
114. Zhou S, Cerny AM, Bowen G, Chan M, Knipe DM, Kurt-Jones EA et al. Discovery of a novel TLR2 signaling inhibitor with anti-viral activity. Antiviral Res 2010; 87: 295-306.
115. Davis CN, Mann E, Behrens MM, Gaidarova S, Rebek M, Rebek J Jr et al. MyD88-dependent and -independent signaling by IL-1 in neurons probed by bifunctional Toll/IL-1 receptor domain/BB-loop mimetics. Proc Natl Acad Sci USA 2006; 103: 2953-2958.
116. Loiarro M, Capolunghi F, Fanto N, Gallo G, Campo S, Arseni B et al. Pivotal advance: inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukocyte Biol 2007; 82: 801-810.
117. Butt AQ, Ahmed S, Maratha A, Miggin SM. 14-3-3{Epsilon} and 14-3-3sigma inhibit Toll-like receptor (TLR)-mediated proinflammatory cytokine induction. J Biol Chem 2012; 287: 38665-38679.
118. Chen Q, Wang H, Liu Y, Song Y, Lai L, Han Q et al. Inducible microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1beta production in macrophages by targeting STAT3. PLoS One 2012; 7: e42971.
119. Gonzalez-Lopez A, Aguirre A, Lopez-Alonso I, Amado L, Astudillo A, Fernandez-Garcia MS et al. MMP-8 deficiency increases TLR/RAGE ligands S100A8 and S100A9 and exacerbates lung inflammation during endotoxemia. PLoS One 2012; 7: e39940.
120. Ito H, Hamerman JA. TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells. Eur J Immunol 2012; 42: 176-185.
121. Schneider M, Zimmermann AG, Roberts RA, Zhang L, Swanson KV, Wen H et al. The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nat Immunol 2012; 13: 823-831.
122. Basith S, Manavalan B, Lee G, Kim SG, Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin Therap Patents 2011; 21: 927-944.